Marcelo Bigal, MD, PhD
June 26, 2015 | Neurology
Author and Disclosure Information
Dr. Bigal discusses the findings from two phase IIb clinical trials of TEV-48125, a CGRP monoclonal antibody, for the preventive treatment of chronic migraine and for high-frequency episodic migraine.